Structural profiles of TP 53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma : an international collaborative study

Ken H. Young,1-3 Karen Leroy,4 Michael B. Møller,5 Gisele W. B. Colleoni,6 Margarita Sánchez-Beato,7 Fábio R. Kerbauy,6 Corinne Haioun,4 Jens C. Eickhoff,1-3 Allen H. Young,1-3 Philippe Gaulard,4 Miguel A. Piris,7 Terry D. Oberley,1-3 William M. Rehrauer,1-3 Brad S. Kahl,1-3 James S. Malter,1-3 Elias Campo,8 Jan Delabie,9 Randy D. Gascoyne,10 Andreas Rosenwald,11 Lisa Rimsza,12 James Huang,13 Rita M. Braziel,13 Elaine S. Jaffe,14 Wyndham H. Wilson,14 Louis M. Staudt,14 Julie M. Vose,15 Wing C. Chan,15 Dennis D. Weisenburger,15 and Timothy C. Greiner15

[1]  L. Staudt,et al.  Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. , 2007, Blood.

[2]  E. Campo,et al.  Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Blandino,et al.  Mutant p53 proteins: Between loss and gain of function , 2007, Head & neck.

[4]  M. Hollstein,et al.  p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.

[5]  T. Greiner.  Enhanced Detection of TP53 Mutations Using a GC-clamp in Denaturing High Performance Liquid Chromatography , 2007, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[6]  W. Wilson,et al.  Drug resistance in diffuse large B-cell lymphoma. , 2006, Seminars in hematology.

[7]  T. Naoe,et al.  Promoter Hypermethylation of the DNA-Repair Gene O6-Methylguanine—DNA Methyltransferase and p53 Mutation in Diffuse Large B-cell Lymphoma , 2006, International journal of hematology.

[8]  A. Levine,et al.  The P53 pathway: what questions remain to be explored? , 2006, Cell Death and Differentiation.

[9]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[10]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M. Shipp.  New concepts in treatment approaches and prognostic factors in aggressive NHL. , 2006, Clinical advances in hematology & oncology : H&O.

[12]  V. Rotter,et al.  Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53 , 2006, Oncogene.

[13]  P. Hall,et al.  Assessing p53 in clinical contexts: unlearned lessons and new perspectives , 2006, The Journal of pathology.

[14]  D. Kerr,et al.  The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Soussi,et al.  p53 mutation heterogeneity in cancer. , 2005, Biochemical and biophysical research communications.

[16]  G. Lozano,et al.  What have animal models taught us about the p53 pathway? , 2005, The Journal of pathology.

[17]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[18]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[19]  J. Kobarg,et al.  Detection and Possible Prognostic Relevance of p53 Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature , 2004, Leukemia & lymphoma.

[20]  R. Mariani-Costantini,et al.  TP53 in gastric cancer: Mutations in the L3 loop and LSH motif DNA‐binding domains of TP53 predict poor outcome , 2004, Journal of cellular physiology.

[21]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[22]  David V Glidden,et al.  Modelling clustered survival data from multicentre clinical trials , 2004, Statistics in medicine.

[23]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[24]  L. Staudt,et al.  Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.

[25]  Brian J. Smith,et al.  The impact of p53 protein core domain structural alteration on ovarian cancer survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  A. Inga,et al.  Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Arsène,et al.  Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France). , 2003, Mutagenesis.

[29]  V. Rotter,et al.  TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance , 2003, Human mutation.

[30]  B. Cheson.  Hematologic malignancies: new developments and future treatments. , 2002, Seminars in oncology.

[31]  P. Gaulard,et al.  p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[33]  M. Oren,et al.  Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities* , 2002, The Journal of Biological Chemistry.

[34]  A. Ganser,et al.  Tumor suppressor genes in normal and malignant hematopoiesis , 2002, Oncogene.

[35]  S. Barrans,et al.  Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. , 2002, Blood.

[36]  Alison L. Cuff,et al.  Integrating mutation data and structural analysis of the TP53 tumor‐suppressor protein , 2002, Human mutation.

[37]  M. Olivier,et al.  TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. , 2001, Seminars in cancer biology.

[38]  A. Sánchez-Aguilera,et al.  Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. , 2001, The American journal of pathology.

[39]  P. Slootweg,et al.  Gain-of-function mutations in the tumor suppressor gene p53. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[41]  R. Kanamaru,et al.  Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma. , 1999, Anti-cancer drug design.

[42]  D. Louis,et al.  Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma , 1999, Leukemia.

[43]  A. Levine,et al.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.

[44]  J. Cleveland,et al.  Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.

[45]  S. Deb,et al.  `Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain , 1998, Oncogene.

[46]  F. Bosch,et al.  TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer , 1998, Oncogene.

[47]  P. Koduru,et al.  Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. , 1997, Blood.

[48]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[49]  C. Preudhomme,et al.  THE CLINICAL SIGNIFICANCE OF MUTATIONS OF THE P52 TUMOUR SUPPRESSOR GENE IN HAEMATOLOGICAL MALIGNANCIES , 1997, British journal of haematology.

[50]  H. Saito,et al.  Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[51]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[52]  S. Deb,et al.  Transcriptional activation of the human epidermal growth factor receptor promoter by human p53 , 1996, Molecular and cellular biology.

[53]  H. Werner,et al.  Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[54]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[55]  M. Kaneuchi,et al.  The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. , 1996, Oncogene.

[56]  W. Chan,et al.  p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.

[57]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[58]  E. Hovig,et al.  TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains , 1995, Genes, chromosomes & cancer.

[59]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[60]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[61]  W. Kolch,et al.  Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. , 1994, Oncogene.

[62]  D. Longo,et al.  p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.

[63]  E. Cesarman,et al.  High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. , 1993, The American journal of pathology.

[64]  P. Sehgal,et al.  Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. , 1993, The Journal of biological chemistry.

[65]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[66]  M. Subler,et al.  Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells , 1992, Journal of virology.

[67]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[68]  K. Husgafvel‐Pursiainen,et al.  Analysis of TP53 gene mutations in human lung cancer: comparison of capillary electrophoresis single strand conformation polymorphism assay with denaturing gradient gel electrophoresis and direct sequencing. , 2006, Cancer detection and prevention.

[69]  L. Staudt,et al.  The biology of human lymphoid malignancies revealed by gene expression profiling. , 2005, Advances in immunology.

[70]  M. Scian,et al.  Tumor-derived p53 mutants induce NF-kappaB2 gene expression. , 2005, Molecular and cellular biology.

[71]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[72]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[73]  A. Flahault,et al.  p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  A. Børresen-Dale,et al.  TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[76]  C. Bellamy,et al.  p53 and apoptosis. , 1997, British medical bulletin.

[77]  T. Soussi,et al.  The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. , 1996, Molecular medicine today.

[78]  D.,et al.  Regression Models and Life-Tables , 2022 .